Anti-Hormonal Therapies for Premenopausal Patients – What did we Learn from the TEXT/SOFT Trials?

Publisher： Bentham Science Publishers

E-ISSN： 1876-1038|10|2|90-100

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.10, Iss.2, 2015-01, pp. : 90-100

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

What can we learn from ‘dropouts’ in clinical trials?

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 2, 2018-02 ,pp. : 318-319

John Wiley & Sons Inc

Access to resources Recommend Favorite

What Can We Learn from Herceptin® Trials in Metastatic Breast Cancer?

By  

Oncology, Vol. 63, Iss. 1, 2002-11 ,pp. : 39-46

Karger

Access to resources Recommend Favorite

Targeted Therapies and Survival: What We Can Learn from Studies in Advanced Renal Cell Carcinoma

By  

Oncology, Vol. 84, Iss. 1, 2012-10 ,pp. : 39-42

Karger

Access to resources Recommend Favorite

B‐type natriuretic peptide and heart failure: what can we learn from clinical trials?

By  

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (ELECTRONIC), Vol. 42, Iss. 9, 2015-09 ,pp. : 881-887

John Wiley & Sons Inc

Access to resources Recommend Favorite

What can we learn from international comparisons of costs by DRG?

By Pirson M.   Schenker L.   Martins D.   Dung Duong   Chalé J.   Leclercq P.  

The European Journal of Health Economics, Vol. 14, Iss. 1, 2013-02 ,pp. : 67-73

Springer Publishing Company

Access to resources Recommend Favorite